Skip to main content
NCBI home page
Oncotarget logoLink to Oncotarget
. 2014 Dec 11;6(4):2466–2482. doi: 10.18632/oncotarget.2967

Genetic alterations of histone lysine methyltransferases and their significance in breast cancer

Lanxin Liu 1,#, Sarah Kimball 1,#, Hui Liu 1, Andreana Holowatyj 1, Zeng-Quan Yang 1
PMCID: PMC4385864  PMID: 25537518

Abstract

Histone lysine methyltransferases (HMTs), a large class of enzymes that catalyze site-specific methylation of lysine residues on histones and other proteins, play critical roles in controlling transcription, chromatin architecture, and cellular differentiation. However, the genomic landscape and clinical significance of HMTs in breast cancer remain poorly characterized. Here, we conducted a meta-analysis of approximately 50 HMTs in breast cancer and identified associations among recurrent copy number alterations, mutations, gene expression, and clinical outcome. We identified 12 HMTs with the highest frequency of genetic alterations, including 8 with high-level amplification, 2 with putative homozygous deletion, and 2 with somatic mutation. Different subtypes of breast cancer have different patterns of copy number and expression for each HMT gene. In addition, chromosome 1q contains four HMTs that are concurrently or independently amplified or overexpressed in breast cancer. Copy number or mRNA expression of several HMTs was significantly associated with basal-like breast cancer and shorter patient survival. Integrative analysis identified 8 HMTs (SETDB1, SMYD3, ASH1L, SMYD2, WHSC1L1, SUV420H1, SETDB2, and KMT2C) that are dysregulated by genetic alterations, classifying them as candidate therapeutic targets. Together, our findings provide a strong foundation for further mechanistic research and therapeutic options using HMTs to treat breast cancer.

Keywords: breast cancer, histone lysine methyltransferase, gene amplification, deletion, mutation

INTRODUCTION

Breast cancer is the most common cancer among women worldwide, with 1.3 million women diagnosed each year and about 500,000 deaths per year from the disease. Distinct subtypes of breast carcinomas that are associated with different clinical outcomes have been identified by expression analysis using microarray-based technology [1, 2]. Five intrinsic molecular subtypes of human breast cancer include Luminal A, Luminal B, human epidermal growth factor receptor 2 (HER2/ERBB2)-positive, basal-like, and normal-like breast cancer [2, 3]. Both Luminal A and Luminal B breast cancers are estrogen receptor (ER) positive, but Luminal B cancers have poorer outcomes [4]. Basal-like breast cancer is especially aggressive as it includes tumors that lack ER, progesterone receptor (PR), and HER2 expression (hence the name “triple-negative”) [5, 6]. These characteristics render conventional therapies ineffective and lead to poor prognosis. By understanding the genetic and epigenetic abnormalities that are associated with the different types of breast cancer, we can identify new subtype-specific targets for therapy.

Histone lysine methylation, which is controlled by histone lysine methyltransferases (HMTs) and demethylases, is an important player in epigenetic regulation [7, 8]. More than 50 human HMTs have been identified [9]. Structurally, the HMTs are a diverse group of proteins that can be broadly categorized into two functional enzymatic families, the SET (Suppressor of variegation, Enhancer of zeste, Trithorax)-domain-containing methyltransferases and the DOT1-like (DOT1L) lysine methyltransferases [8, 9]. HMTs catalyze the transfer of one to three methyl groups from S-adenosylmethionine to specific lysine residues on histones [7]. Depending on the site and degree of methylation (mono-, di-, or trimethylated), lysine methylation can lead to various biological outcomes, including the regulation of chromatin organization and gene transcription.

Recent studies indicated that dysregulation of HMTs can lead to imbalances in histone methylation pathways and contribute to the pathogenesis of a wide array of human cancers, including breast cancer [10-12]. For example, we demonstrated that the methyltransferase gene WHSC1L1 (Wolf-Hirschhorn syndrome candidate 1-like 1) is significantly amplified and overexpressed in breast cancer. We also demonstrated that WHSC1L1 acts as a transforming gene: stable WHSC1L1 overexpression in nontumorigenic mammary epithelial MCF10A cells induced transformed phenotypes, whereas WHSC1L1 knockdown inhibited proliferation of WHSC1L1-amplified breast cancer cells in vitro. EZH2, a histone 3 lysine 27 (H3K27) methyltransferase, is also significantly overexpressed in breast cancers, and elevated expression of EZH2 protein has been associated with poor prognoses for inflammatory basal-like breast cancers [13, 14].

Emerging evidence indicates that genetic alterations of several HMTs that have oncogenic or tumor-suppressor functions play important roles in cancer initiation and progression [10, 11, 15]. Despite the extensive DNA and RNA sequencing data, such as The Cancer Genome Atlas (TCGA), in human cancer, there has been no systematic analysis of genomic anomalies and expression of HMTs in different subtypes of breast cancer. In addition, the clinical relevance of genetic alterations for each HMT in breast cancer has yet to be fully explored. Thus, our goals were to determine the genomic landscape and significance of HMTs in different types of breast cancers and to evaluate their diagnostic and prognostic potentials.

RESULTS

Genetic alterations of HMTs in breast cancer

Copy number alteration (CNA) and somatic mutation are important mechanisms that activate oncogenes or inactivate tumor suppressors in human cancers [16, 17]. We hypothesized that HMTs with recurrent CNA or mutation would be more likely to play critical roles in breast cancer. Thus, to systematically investigate genetic alterations of HMTs in breast cancer, we first analyzed the genome sequencing data of 958 breast cancer samples from the TCGA database via cBioPortal [18, 19]. In cBioPortal, copy numbers were computed using a GISTIC (Genomic Identification of Significant Targets in Cancer) algorithm, which identified the putative copy number as high-level amplification (+2), low-level gain (+1), diploid (0), heterozygous deletion (−1), or homozygous deletion (−2) [18, 19]. In 958 breast cancer samples, the average CNA rate was 0.15 (range 5.23*10−6 to 0.588), based on the segmented copy number scores of the tumor samples and the paired-normal control.

The human genome encodes 51 proteins with demonstrated or predicted ability to methylate histone lysine residues [9, 20]. Except for DOT1L, the rest of the HMTs contain a characteristic SET enzymatic domain and can be divided into four subgroups according to phylogenetic analysis (Table 1 and Supplementary Figure S1) [7, 9]. We analyzed copy numbers (excluding that of KMT2B, for which data were not available in the cBioPortal database) and mutations of these 51 HMTs compiled from 958 TCGA breast cancer specimens. As shown in Table 2, we discovered distinct patterns of altered copy numbers and mutations of HMTs in breast cancer. Notably, we found that eight HMTs exhibited high-level amplification in more than 5% of breast cancers, and five of these eight HMTs (SMYD3, SETDB1, ASH1L, WHSC1L1, and SMYD2) had high-level amplification in more than 10% of samples. Two HMT genes, PRDM7 and SETDB2, showed homozygous deletion in more than 2% of breast cancers. In addition, two other HMT genes, KMT2C and KMT2D, exhibited somatic mutations in more than 2% of the 958 breast cancer samples.

Table 1. Summary of identified human HMTs and their substrates.

Official Symbol Other Aliases Gene ID Gene Location Histone Substrates
EHMT1 GLP; GLP1; KMT1D; FP13812; EUHMTASE1; Eu-HMTase1; bA188C12.1 79813 9q34.3 H3K9; H1.2K187
EHMT2 G9A; BAT8; GAT8; NG36; KMT1C; C6orf30 10919 6p21.31 H3K9; H3K27; H3K56; H1.2K187; H1.4K26;
SUV39H1 MG44; KMT1A; SUV39H; H3-K9-HMTase 1 6839 Xp11.23 H3K9
SUV39H2 KMT1B 79723 10p13 H3K9
SETDB1 ESET; KG1T; KMT1E; TDRD21; H3-K9-HMTase4 9869 1q21.3 H3K9
SETDB2 CLLD8; CLLL8; KMT1F; C13orf4 83852 13q14.2 H3K9
SETD2 HYPB; SET2; HIF-1; HIP-1; KMT3A; HBP231; HSPC069; p231HBP 29072 3p21.31 H3K36
KMT2E MLL5; NKp44L; HDCMC04P 55904 7q22.3 H3K4
SETD5 55209 3p25.3
SETMAR Mar1; HsMar1; METNASE 6419 3p26.1 H3K36
EZH1 KMT6B 2145 17q21.2 H3K27
EZH2 WVS; ENX1; EZH1; KMT6; WVS2; ENX-1; EZH2b; KMT6A 2146 7q36.1 H3K27
SETD7 KMT7; SET7; SET9; SET7/9 80854 4q31.1 H3K4
KMT2B HRX2; MLL2; MLL4; TRX2; WBP7; MLL1B; WBP-7 9757 19q13.12 H3K4
KMT2C HALR; MLL3 58508 7q36.1 H3K4
SETD1A Set1; KMT2F; Set1A 9739 16p11.2 H3K4
SETD1B KMT2G; Set1B 23067 12q24.31 H3K4
KMT2A HRX; MLL; MLL1; TRX1; ALL-1; CXXC7; HTRX1; MLL1A; WDSTS; MLL/GAS7; TET1-MLL 4297 11q23.3 H3K4
KMT2D ALR; KMS; MLL2; MLL4; AAD10; KABUK1; TNRC21; CAGL114 8085 12q13.12 H3K4
SETD8 SET8; KMT5A; SET07; PR-Set7 387893 12q24.31 H4K20
MECOM EVI1; MDS1; PRDM3; MDS1-EVI1; AML1-EVI-1 2122 3q26.2 H3K9me1
PRDM16 MEL1; LVNC8; PFM13; CMD1LL 63976 1p36.32 H3K9me1
PRDM13 PFM10; MU-MB-20.220 59336 6q16.2
PRDM8 PFM5 56978 4q21.21 H3K9
PRDM1 BLIMP1; PRDI-BF1 639 6q21
PRDM2 RIZ; KMT8; RIZ1; RIZ2; MTB-ZF; HUMHOXY1 7799 1p36.21 H3K9
PRDM10 PFM7 56980 11q24.3
PRDM12 PFM9 59335 9q34.12
PRDM6 93166 5q23.2
PRDM14 PFM11 63978 8q13.3
PRDM4 PFM1 11108 12q23.3
PRDM15 PFM15; ZNF298; C21orf83 63977 21q22.3
PRDM5 BCS2; PFM2 11107 4q27
PRDM7 PFM4; ZNF910 11105 16q24.3
PRDM9 PFM6; MSBP3; PRMD9; ZNF899; MEISETZ 56979 5p14.2 H3K4
PRDM11 PFM8 56981 11p11.2
SUV420H1 CGI85; KMT5B; CGI-85 51111 11q13.2 H4K20
SUV420H2 KMT5C 84787 19q13.42 H4K20
ASH1L ASH1; KMT2H; ASH1L1 55870 1q22 H3K4; H3K36
SETD3 C14orf154 84193 14q32.2
SETD4 C21orf18; C21orf27 54093 21q22.12
SETD6 79918 16q21
SMYD1 BOP; KMT3D; ZMYND18; ZMYND22 150572 2p11.2 H3K4
SMYD3 KMT3E; ZMYND1; ZNFN3A1; bA74P14.1 64754 1q44 H3K4
SMYD2 KMT3C; HSKM-B; ZMYND14 56950 1q32.3 H3K4; H3K36
SMYD4 ZMYND21 114826 17p13.3
SMYD5 RRG1; RAI15; NN8-4AG; ZMYND23 10322 2p13.2
NSD1 STO; KMT3B; SOTOS; ARA267; SOTOS1 64324 5q35.2 H3K36
WHSC1 WHS; NSD2; TRX5; MMSET; REIIBP 7468 4p16.3 H3K36; H4K20
WHSC1L1 NSD3; pp14328 54904 8p11.23 H3K4; H3K27
DOT1L DOT1; KMT4 84444 19p13.3 H3K79
Open in a new tab

Table 2. Frequency of HMT copy number alterations and mutations.

Gene Gene Location Amp Gain Diploid Hetloss Homdel Mutation
SMYD3 1q44 14.61 58.87 23.17 3.13 0.21 0.52
SETDB1 1q21.3 14.41 57.83 25.89 1.88 0.00 1.15
ASH1L 1q22 12.84 61.17 24.43 1.57 0.00 1.77
WHSC1L1 8p11.23 12.84 24.53 37.37 23.70 1.57 0.52
SMYD2 1q32.3 12.11 61.59 23.28 2.92 0.10 0.21
PRDM14 8q13.3 9.71 45.30 40.08 4.80 0.10 0.31
SUV420H1 11q13.2 5.64 22.65 57.41 14.20 0.10 0.84
SETD1A 16p11.2 5.01 46.87 39.77 8.35 0.00 0.42
MECOM 3q26.2 4.38 27.56 62.53 5.53 0.00 0.63
PRDM1 6q21 2.92 14.51 51.36 30.90 0.31 0.84
SUV39H2 10p13 2.82 23.90 61.48 11.69 0.10 0.10
SUV420H2 19q13.42 2.71 22.44 60.23 14.51 0.10 0.21
SETMAR 3p26.1 2.19 17.95 63.78 15.66 0.42 0.21
SETD5 3p25.3 2.09 17.85 64.61 15.34 0.10 0.52
PRDM9 5p14.2 1.88 32.05 56.05 9.81 0.21 0.73
EZH1 17q21.2 1.46 18.79 45.09 34.13 0.52 0.31
PRDM11 11p11.2 1.46 16.81 64.20 17.33 0.21 0.10
EHMT2 6p21.31 1.36 23.80 60.23 14.61 0.00 0.42
PRDM13 6q16.2 1.36 14.30 51.57 32.57 0.21 0.31
NSD1 5q35.2 1.25 24.84 55.74 17.85 0.31 1.04
PRDM15 21q22.3 1.25 20.98 61.06 16.49 0.21 0.63
PRDM16 1p36.32 0.94 7.20 52.92 38.00 0.94 0.42
SUV39H1 Xp11.23 0.94 15.34 67.01 16.28 0.42 0.21
EZH2 7q36.1 0.84 24.43 57.52 16.91 0.31 0.31
KMT2C 7q36.1 0.84 23.80 55.53 18.79 1.04 6.99
SETD4 21q22.12 0.84 20.88 62.32 15.66 0.31 0.00
PRDM7 16q24.3 0.73 8.87 26.10 61.90 2.40 0.21
SETD8 12q24.31 0.73 16.49 62.94 19.62 0.21 0.31
EHMT1 9q34.3 0.63 14.41 57.83 26.62 0.52 0.94
KMT2E 7q22.3 0.63 25.37 59.50 14.41 0.10 1.15
PRDM12 9q34.12 0.63 13.26 58.56 27.35 0.21 0.10
PRDM8 4q21.21 0.63 11.69 60.65 26.93 0.10 0.42
SETD1B 12q24.31 0.63 16.70 62.42 20.04 0.21 0.63
SETD3 14q32.2 0.63 14.30 55.74 29.02 0.31 0.31
PRDM10 11q24.3 0.52 9.50 43.63 44.78 1.57 0.73
WHSC1 4p16.3 0.52 10.13 57.41 31.21 0.73 0.42
KMT2D 12q13.12 0.42 19.73 65.76 14.09 0.00 2.40
PRDM5 4q27 0.42 10.02 60.54 29.02 0.00 0.31
DOT1L 19p13.3 0.31 10.75 56.37 31.63 0.94 0.84
PRDM4 12q23.3 0.31 16.49 64.82 18.27 0.10 0.31
PRDM6 5q23.2 0.31 18.27 57.20 23.70 0.52 0.10
SETD6 16q21 0.31 9.08 28.71 61.06 0.84 0.00
SETD7 4q31.1 0.31 9.60 60.65 29.33 0.10 0.52
SMYD4 17p13.3 0.31 6.37 34.34 58.25 0.73 0.52
SMYD5 2p13.2 0.31 16.18 68.27 15.14 0.10 0.21
PRDM2 1p36.21 0.21 5.32 53.13 40.81 0.52 0.73
SMYD1 2p11.2 0.21 15.03 69.10 15.55 0.10 0.52
KMT2A 11q23.3 0.10 9.29 41.65 48.02 0.94 1.67
SETD2 3p21.31 0.10 9.29 59.71 30.48 0.42 1.57
SETDB2 13q14.2 0.10 7.52 46.35 43.95 2.09 0.21
Open in a new tab

Footnote: Amp=high-level amplification; Gain=low-level gain; Hetloss=heterozygous deletion; Homdel= homozygous deletion. Genes were ranked based on the frequency of high-level amplification.

To determine whether the genetic alteration of each HMT is specific to a breast cancer subtype, we performed an independent analysis of copy number and mutation in different subtypes of breast cancer. Of the 958 breast cancer samples, 492 had subtype data available, including 8 normal-like, 220 Luminal A, 121 Luminal B, 55 HER2+, and 88 basal-like breast cancers [6]. Because the normal-like subtype had such a small sample size (n=8), those samples were excluded from this analysis. As shown in Supplementary Tables S1 and S2, basal-like breast cancer had the highest frequencies of HMT gene amplification, deletion, and mutation, whereas Luminal A had the lowest frequencies among the four subtypes in every category of genetic alteration.

In addition, each HMT showed different frequencies of CNA or mutation in different subtypes of breast cancer. Among the eight most frequently amplified HMTs (totaling more than 5% of 958 samples), the frequencies of ASH1L, SETDB1, and SMYD3 amplification were dramatically higher in basal-like breast cancer, with more than 25% of tumors exhibiting high-level amplification compared with the other three subtypes (Figure 1A and Supplementary Table S1). In contrast, WHSC1L1 exhibited the highest frequency of amplification in the Luminal B subtype (19%), and SETD1A had the highest frequency of amplification in the Luminal A subtype (7.27%) (Figure 1A). Of the two most common HMTs with homozygous deletions, SETDB2 exhibited the highest frequency of homozygous deletion (6.82%) in basal-like samples, and PRDM7 was most frequent (5.79%) in Luminal B breast cancer (Figure 1B). Of the most commonly mutated HMTs, KMT2C was most frequently mutated in Luminal A and KMT2D in HER+ breast cancer (Figure 1C). These data indicate that breast cancer, particularly the basal-like subtype, has a high frequency of CNAs and somatic mutations in several HMTs, including amplification of ASH1L, SETDB1, and SMYD3, as well as homozygous deletion of SETDB2.

Figure 1. Frequencies of HMTs.

Figure 1

Open in a new tab

(A) High-level amplification of eight HMTs, (B) homozygous deletion of two HMTs, and (C) mutation of two HMTs in 492 primary breast cancer specimens from The Cancer Genome Atlas across different types of breast cancer.

Expression profiling of HMTs in breast cancer

Correlation between gene expression and copy number has been used widely to prioritize candidate driver oncogenes in human cancer, because mRNA overexpression can better translate the effect of elevated copy number to cancer initiation and progression. Therefore, we next analyzed the correlation between copy number and mRNA level of 48 HMTs from 958 sequenced breast cancer specimens. Three HMTs (KMT2B, KMT2D, and PRDM9) were excluded from analysis because they lacked RNA sequencing data. To weigh the benefits of different statistical analyses, we compared three different correlation tests—Spearman, Kendall, and Pearson. The rank correlation coefficients among the three statistical tests were similar for the HMTs, specifically by mostly keeping the relative order constant (Table 3). The highest weight was given to the Spearman correlation coefficient, as it measures the relationship between rank-ordered variables and relates the two variables while conserving the order of data points. As shown in Table 3, except for MECOM, DNA copy number versus mRNA expression correlations for 47 HMT genes were positive, with 12 of them (WHSC1L1, SETD3, SETD6, SETDB1, SMYD4, EZH1, SUV420H1, EHMT1, SETD2, SUV39H2, PRDM4, and SETDB2) having a Spearman correlation coefficient (r) greater than 0.5. Among the 48 HMTs, WHSC1L1 had the highest correlation by both Spearman (r=0.737) and Kendall (r=0.604) analyses, consistent with our previous findings that WHSC1L1 is an amplified gene in breast cancer [12, 21].

Table 3. Associations between CNA and expression, and comparison of mRNA expression between basal and nonbasal breast cancer subtypes.

Gene DNA/mRNA Correlation Basal/non-basal Comparison
Spearman Kendall Pearson T Stat P value
WHSC1L1 0.737 0.604 0.460 −1.815 3.65E-02
SETD3 0.663 0.545 0.612 −4.291 2.30E-05
SETD6 0.625 0.503 0.615 4.671 5.41E-06
SETDB1 0.624 0.506 0.560 4.115 4.38E-05
SMYD4 0.614 0.498 0.626 −0.344 3.66E-01
EZH1 0.612 0.485 0.562 −6.282 6.41E-09
SUV420H1 0.553 0.448 0.599 −0.742 2.30E-01
EHMT1 0.543 0.440 0.547 −7.336 5.42E-11
SETD2 0.520 0.417 0.500 −3.102 1.30E-03
SUV39H2 0.507 0.406 0.573 8.950 2.84E-14
PRDM4 0.505 0.409 0.516 −4.631 6.31E-06
SETDB2 0.501 0.398 0.433 −2.541 6.41E-03
SETD1B 0.481 0.385 0.451 −4.121 4.29E-05
EHMT2 0.478 0.386 0.470 5.621 1.13E-07
SETD1A 0.471 0.377 0.451 0.294 3.85E-01
SETD4 0.430 0.347 0.462 0.689 2.46E-01
PRDM2 0.428 0.344 0.422 −1.400 8.25E-02
SETD5 0.418 0.337 0.469 1.931 2.84E-02
SMYD5 0.402 0.324 0.451 3.632 2.38E-04
KMT2A 0.401 0.316 0.404 0.881 1.90E-01
SETMAR 0.388 0.309 0.435 −1.719 4.46E-02
SETD8 0.367 0.292 0.387 3.239 8.50E-04
NSD1 0.358 0.283 0.387 −1.936 2.81E-02
PRDM11 0.355 0.281 0.372 1.557 6.15E-02
WHSC1 0.345 0.278 0.365 3.625 2.43E-04
SMYD2 0.343 0.270 0.336 7.273 7.23E-11
PRDM15 0.339 0.267 0.367 3.895 9.63E-05
ASH1L 0.317 0.248 0.310 −2.722 3.92E-03
SETD7 0.316 0.252 0.325 −9.245 7.08E-15
SMYD3 0.311 0.242 0.213 −6.056 1.73E-08
EZH2 0.300 0.235 0.317 8.004 2.43E-12
PRDM10 0.278 0.220 0.309 −3.070 1.43E-03
SUV420H2 0.267 0.211 0.329 −0.384 3.51E-01
KMT2C 0.261 0.205 0.262 −2.557 6.15E-03
PRDM13 0.252 0.224 0.166 4.209 3.11E-05
DOT1L 0.237 0.188 0.268 2.605 5.40E-03
PRDM7 0.227 0.200 0.177 2.538 6.47E-03
PRDM6 0.197 0.155 0.031 −6.342 4.91E-09
KMT2E 0.194 0.154 0.210 −2.351 1.05E-02
PRDM5 0.154 0.123 0.200 −0.757 2.26E-01
PRDM14 0.123 0.115 0.057 −1.054 1.47E-01
PRDM12 0.110 0.086 0.113 1.168 1.23E-01
PRDM16 0.092 0.074 0.122 0.495 3.11E-01
PRDM1 0.068 0.053 0.086 2.238 1.39E-02
SMYD1 0.063 0.050 −0.002 1.419 7.98E-02
PRDM8 0.035 0.027 0.045 0.380 3.52E-01
SUV39H1 0.016 0.011 0.077 5.415 2.69E-07
MECOM −0.079 −0.063 −0.034 −0.261 3.97E-01
Open in a new tab

Footnote: Genes were ranked based on the Spearman correlation coefficient. Significantly higher expression of HMTs in the basal-like subtype is highlighted in dark gray, and significantly lower expression is highlighted in little gray. T stat represents the T statistic, which is equivalent to the number of standard deviations of mRNA expression levels between the basal-like and nonbasal breast cancer samples. A positive value means that the basal-like subtype has a higher value, and a negative value means that the basal-like subtype has a lower value than the nonbasal breast cancer samples.

Basal-like breast cancer, the most aggressive subtype, is associated with higher rates of metastasis and death [22]. We next sought to compare expression levels of the 48 HMTs between basal and non-basal subtypes in the 492 TCGA breast cancer samples with subtype information. The significance of difference for each HMT between the basal-like and the other subtypes was calculated using Student's t-test. In the basal-like subtype, compared with non-basal subtypes, we found that the expression levels of 12 HMTs (SETDB1, SMYD2, SUV39H2, EHMT2, SUV39H1, EZH2, WHSC1, SMYD5, PRDM15, SETD8, PRDM13, and SETD6) were significantly higher (p<0.001), and the expression levels of 8 HMTs (SMYD3, SETD3, EZH1, EHMT1, PRDM4, SETD1B, SETD7, and PRDM6) were significantly lower (p<0.001) (Figure 2 and Table 3). Notably, our analysis validated that EZH2 exhibits significantly higher expression in basal-like breast cancer, consistent with previous results [14, 23]. Conversely, WHSC1L1 showed moderately higher expression (t=−1.815, p=0.036) in non-basal subtypes, which supports our other findings that it is amplified more in Luminal subtypes and shows high correlation between copy number and mRNA expression (Figure 1A, Table 2) [12, 21].

Figure 2. Heatmap of HMT expression profiles in different types of breast cancer.

Figure 2

Open in a new tab

The breast cancer samples used in this analysis included 8 normal-like, 220 Luminal A, 121 Luminal B, 55 HER2+, and 88 basal-like breast cancers. Significantly higher-expressed genes (p<0.001) in basal-like tumors are shown at the top, indicated by a red box; and lower-expressed genes (p<0.001) in basal-like tumors are indicated by a blue box.

KMT2C and KMT2D mutations in breast cancer

Because KMT2C and KMT2D are the most frequently mutated HMT genes in breast cancers, at rates of 6.99% and 2.40%, respectively (Table 2), we performed a comprehensive analysis of the KMT2C and KMT2D mutation spectrum in 958 breast cancer samples. As shown in Figure 3, we identified a total of 80 KMT2C mutations, consisting of 26 missense mutations, 23 nonsense mutations, 17 frameshift deletions, 12 frameshift insertions, 1 splice, and 1 inframe insertion. Eight tumor samples had two mutations, and two samples had four mutations in the KMT2C gene. For example, sample TCGA-AC-A23H contained three missense mutations (D3264N, E3724K, and D4344H) and one nonsense mutation (Q1218*). In the KMT2D gene, 25 mutations were identified, most of them missense mutations (Figure 3A). KMT2C and 2D are large proteins (approximately 5000 amino acids) that contain the zf-HC5HC2H, PHD, FYRN, and FYRC domains and the carboxy-terminal SET domain. Figure 3B shows the distribution of KMT2C and KMT2D mutations in 958 breast cancer samples across protein domains; most of the mutations are localized to the amino-terminal end of the SET domain. Previous studies demonstrated that mice lacking the KMT2C catalytic SET domain developed ureteric tumors, which supports its hypothesized role as a tumor suppressor [24]. Therefore, we predict that mutations at the amino terminus of KMT2C and KMT2D SET domains (Supplementary Table S3) might result in the truncation of the SET domain or loss of function of KMT2C and/or KMT2D methyltransferases, subsequently contributing to breast cancer initiation and progression.

Figure 3. KMT2C and KMT2D mutational spectrum in breast cancer.

Figure 3

Open in a new tab

(A) Frequency of each mutation type for KMT2C from 958 breast cancer samples. The data were obtained from The Cancer Genome Atlas database via cBioPortal. (B) The images show protein domains and the positions of specific mutations of KMT2C and KMT2D. A red dot indicates a nonsense mutation, frameshift deletion, insertion, or splice; a green dot indicates a missense mutation; and a black dot indicates an inframe insertion or deletion.

Amplification/overexpression of multiple HMTs from chromosome 1q

Among the five most frequently amplified HMT genes (frequency>10%) in breast cancers, four were localized on the long arm of chromosome 1, with SETDB1 at 1q21.3, ASH1L at 1q22, SMYD2 at 1q32.3, and SMYD3 at 1q44 (Figure 4). Of the 958 breast cancer samples, 215 (22.44%) contained high-level amplification in at least one locus of these four genes (Figure 4A). Of those 215 samples, 65 had amplification in all four loci, while 23 samples were amplified only at SETDB1, 8 only at ASH1L, 12 only at SMYD2, and 21 only at SMYD3 (Figure 4A). In addition, 111 of 215 samples were co-amplified at ASH1L and SETDB1, and this amplicon (1q21-22) spans approximately 4 Mb in basal-like breast cancer [6]. We assume that in the 65 samples containing co-amplification of SETDB1, ASH1L, SMYD2, and SMYD3, the whole arm of chromosome 1q is amplified. We found that amplification of the whole arm of 1q is more common in Luminal subtypes (Luminal A, 7.73%, Luminal B, 8.26%) than in HER2+ (5.45%) and basal (5.68%) subtypes.

Figure 4. High-level amplification of four HMT genes at chromosome 1q in breast cancer.

Figure 4

Open in a new tab

(A) Copy numbers of SETDB1, ASH1, SMYD2, and SMYD3 were obtained from the Oncoprint output of The Cancer Genome Atlas breast cancer data (cBioPortal). A red rectangle indicates high-level amplification; blue rectangle, homozygous deletion; grey rectangle, unaltered. SASS represents amplification of all four (SETDB1, ASH1, SMYD2, and SYMD3) loci; SE1 represents SETDB1 locus only; AS, ASH1L only; SM2, SMYD2 only; and SM3, SMYD3 only. (B) Agilent array of comparative genomic hybridization profiles shows amplification/gain of chromosome 1q in three breast cancer cell lines (Colo824, HCC1187, and MCF7, also see Supplementary Table S4).

In breast cancer, cell lines mirror many of the molecular characteristics of the tumors from which they were derived, so we used a panel of breast cancer cell lines to further investigate the genetic landscape of HMTs, particularly the amplification and overexpression of the four HMTs on chromosome 1q. We first analyzed our own genomic array of comparative genomic hybridization (CGH) data as well as publicly available data for 17 breast cancer cell lines [12, 21, 25]. Seven lines (Colo824, SUM229, SUM149, HCC70, HCC1937, HCC1187, and MDB-MA-468) were of the basal-like subtype, three lines (HCC1954, SUM190, and SUM225) were of the HER2+ subtype, and seven (HCC1428, SUM44, SUM52, T47D, SUM185, ZR-75-1, and MCF7) were of the Luminal subtypes. We found that, similar to primary breast cancer samples, 16 of 17 lines showed gain or amplification in at least one locus of SETDB1, ASH1L, SMYD2, and SMYD3. Six lines (Colo824, HCC70, HCC1187, MDB-MA-468, HCC1954, and ZR-75-1) showed low-level gain across most of chromosome 1q, whereas Colo824 and HCC1187 showed high-level amplification at the SETDB1 locus (Figure 4B and Supplementary Table S4). Notably, MCF7 showed moderate amplification at the SETDB1 locus as well as heterozygous deletions at the ASH1L and SMYD2 loci (Figure 4B and Supplementary Table S4). In addition, consistent with our findings in primary breast cancers, we also found that other HMTs, such as WHSC1L1, SUV420H1, and SETD1A, were commonly gained or amplified, and SETDB2 was commonly lost or deleted in breast cancer cell lines (Supplementary Figure S2).

Next, we performed quantitative RT-PCR (qRT-PCR) analysis to measure the mRNA expression level of eight HMTs (SETDB1, ASH1L, SMYD2, SMYD3, SETD1A, WHSC1L1, SUV420H1, and SETDB2) in 20 breast cancer cell lines. MCF10A, an immortalized but non-tumorigenic breast epithelial cell line, was used as the control. These eight HMTs were chosen because seven of them showed the highest frequency of amplification (>5%), and the eighth, SETDB2, exhibited homozygous deletion in more than 2% of breast cancers. Although PRDM14 and PRDM7 were also among the HMTs with the highest frequency of amplification or homozygous deletion, respectively, in breast cancer, they were excluded from the qRT-PCR analysis because their expression levels in breast cancer cells were too low for detection (data not shown). Figure 5 shows the relative expression of eight HMT genes in 20 breast cancer cell lines compared with MCF10A cells. We found that mRNA levels of SETDB1 were more than two-fold higher in 14 of 20 breast cancer cell lines. For ASH1L, 11 of 20 cell lines; for SMYD2, 14 of 20; and for SMYD3, 6 of 20 breast cancer cell lines had two-fold higher mRNA levels. Notably, Colo824 showed higher expression of four 1q HMTs, with the highest expression of SETDB1 among the 20 breast cancer cell lines. In contrast, MCF7 showed higher expression of SETDB1, but not ASH1L and SMYD2, which is consistent with amplification of SETDB1, but not ASH1L and SMYD2, in this breast cancer cell line (Figure 5). We also found that SMYD3 and WHSC1L1 were prevalently overexpressed in several Luminal breast cancer cell lines. Breast cancer cell lines with deletion of SETDB2, such as SUM229, SUM149, HCC170, and SUM190, showed dramatically lower mRNA levels than MCF10A cells (Figure 5). Similar results were observed in RNA sequencing (RNA-Seq) data from 42 breast cancer cell lines compared with five normal mammary epithelial cell lines (Supplementary Figure S3). These experiments demonstrated that breast cancer cell lines with HMT gene CNAs showed a correlated change in mRNA expression. Thus, these cell lines provide useful preclinical models in which to investigate the biological functions of HMTs and to explore novel inhibitors for targeting HMTs in breast cancer in the future.

Figure 5. mRNA expression levels of eight HMTs in a panel of 20 breast cancer cell lines measured by qRT-PCR.

Figure 5

Open in a new tab

mRNA expression levels in the MCF10A cells, an immortalized but non-tumorigenic breast epithelial cell line, were arbitrarily set as 1. Relative expression levels are shown as fold changes compared with that in MCF10A cells.

HMT copy number and expression are associated with breast cancer patient survival

To investigate the clinical relevance of genetic alterations of HMTs in breast cancer, we examined the relationship between HMT copy number, mRNA expression, and overall patient survival in 770 of 958 breast cancer samples for which detailed survival data were available. To investigate DNA copy number, samples were segregated into the following three groups for each HMT: amp/gain (high-level amplification and low-level gain), diploid, or deletion (heterozygous and homozygous deletion). Log-rank statistical analysis was first used to determine whether an increase or decrease in copy number for each HMT was associated with overall patient survival. We found that for seven HMTs (KMT2C, SETDB2, SETD2, SETMAR, PRDM1, PRDM5, and PRDM8), copy number amp/gain or deletion was significantly associated (p<0.05) with shorter survival in breast cancer patients (Figure 6A and Supplementary Table S5). Both deletion and amp/gain of SETDB2 and SETMAR were associated with shorter patient survival, whereas only amp/gain of PRDM1, PRDM5, and PRDM8 was more likely associated with shorter patient survival (Supplementary Table S5). Most importantly, we discovered that deletion of KMT2C was significantly associated with shorter survival, and amp/gain of this gene was significantly associated with longer survival, compared with patients who had no change in copy number (Figure 6A). However, KMT2C, which has the highest genetic mutation rate of HMTs in breast cancer, showed no significant difference in patient survival with regard to mutation (Supplementary Figure S4).

Figure 6. Kaplan-Meier plots of overall survival associated with.

Figure 6

Open in a new tab

(A) copy number and (B) mRNA expression levels of three HMTs (WHSC1L1, SETDB2, and KMT2C) in breast cancer

To analyze the relationships between HMT mRNA expression and overall patient survival in breast cancer, samples were divided into low (n=385) and high (n=385) groups based on the mRNA expression Z-scores [RNA-Seq V2 RSEM (RNA-Seq by Expectation-Maximization)] of each HMT. Seven HMTs were excluded from survival analysis of mRNA expression because three of them (KMT2B, KMT2D, and PRDM9) lacked RNA sequencing data, and the expression levels for four of them (PRDM7, PRDM13, PRDM14, and SMYD1) were too low to be convincing, as previously noted. Supplementary Table S6 summarizes the results of a log-rank statistical analysis for 44 HMTs in breast cancer. High mRNA levels of WHSC1L1 (p=0.0231), SETD7 (p=0.0021), and SETD5 (p=0.0456) were significantly associated (p<0.05) with shorter survival in breast cancer patients (Figure 6B, Supplementary Table S6). For WHSC1L1, higher mRNA expression had a hazard ratio (HR), a ratio of the probability of death, of 1.659 (95% confidence interval, 1.074 to 2.571) compared with lower mRNA expression in breast cancer. Additionally, high mRNA levels of SUV39H2 (p=0.0506), KMT2A (p=0.0644), NSD1 (p=0.0701), and ASH1L (p=0.0877) showed moderately significant association (p<0.1) with shorter survival in patients with breast cancer (Supplementary Table S6). In contrast, only two HMTs, SETD8 (p=0.0769) and EHMT2 (p=0.0978), displayed low mRNA levels that were moderately associated with shorter survival in patients. KMT2C, which had the highest genetic mutation rate among HMTs in breast cancer, showed no significant difference (p=0.3774) in patient survival in terms of mRNA expression levels (Figure 6B).

We then performed a multivariate analysis (Cox model, n=468) to investigate whether the copy number and/or expression level of each HMT were predictive of poor prognosis compared with standard prognostic markers, including age at diagnosis, ER status, PR status, HER2 status, tumor size, lymph node status, metastasis status, and molecular subtype (basal vs. non-basal). We found that copy number amp/gain of NSD1 or PRDM1, or loss of SETDB2 or PRDM10 was significantly associated (p<0.05) with shorter survival in breast cancer patients (Supplementary Table S7). In addition, we found that high mRNA levels of SETD4 (p=0.0468, HR=1.92), SETD5 (p=0.00231, HR=2.79), or SETD7 (p=0.0391, HR=1.97) were significantly associated (p<0.05) with shorter survival in breast cancer patients (Supplementary Table S8). However, amp/gain or high expression level of SMYD3 was negatively correlated with shorter survival in breast cancer patients (Supplementary Tables S7 and S8).

Integrative identification of critical HMTs in breast cancer

The preceding results suggested the possibility of ranking the importance of HMTs in breast cancer according to CNAs, mutation, mRNA expression, and clinical relevance. We calculated a score for each HMT, where every category counted as one point: when an HMT had high-level amplification (frequency >5%), homozygous deletion (frequency >2%), or mutation (frequency >2%); CNA associated with patient survival (log-rank test p<0.1); DNA/mRNA correlation (r > 0.5, p<0.001); altered expression in aggressive basal-like breast cancer (p<0.001); and mRNA associated with shorter patient survival (log-rank test p<0.1). We then ranked the HMTs, as shown in Table 4, observing that three HMTs (SETDB1, WHSC1L1, and SETDB2) had a score of 3, and five HMTs (ASH1L, SMYD2, SMYD3, SUV420H1, and KMT2C) had a score of 2. These results suggest that these eight HMTs act as drivers of oncogenic processing or as tumor suppressors and have critical roles in breast cancer initiation and progression.

Table 4. Integrative identification of critical HMTs in breast cancer.

Gene CNA/Mutations CNA/Survival DNA/mRNA Expression mRNA/Survival Score
ASH1L + + 2
SETDB1 + + + 3
SMYD2 + + 2
SMYD3 + + 2
WHSC1L1 + + + 3
PRDM14 + 1
SUV420H1 + + 2
SETD1A + 1
PRDM7 + 1
SETDB2 + + + 3
KMT2C + + 2
KMT2D + 1
Open in a new tab

Footnote: CNA/Mutation: high-level amplification, homozygous deletion, or mutation; CNA/Survival: CNA associated with patient survival; DNA/mRNA: DNA/mRNA correlation; Expression: altered expression in aggressive basal-subtype ; and mRNA/Survival: mRNA associated with patient survival.

DISCUSSION

We performed comprehensive genomic and transcriptomic analysis of 51 human HMTs in a panel of breast cancer cell lines and in primary breast cancer samples. Our main findings include the following: (1) we identified 12 HMTs with the highest frequency of genetic alterations, including eight with high-level amplification, two with putative homozygous deletion, and two with somatic mutation; (2) there was a correlation between gene expression and copy number: most HMTs had a positive correlation, and WHSC1L1 had the highest correlation coefficient in breast cancer; (3) different subtypes of breast cancer have different patterns of copy number and expression for each HMT gene; several, including SETDB1 and SMYD2, were highly amplified and overexpressed in basal-like breast cancer; (4) the two most mutated HMTs, KMT2C and KMT2D, exhibited various types of mutation across protein domains, possibly resulting in loss of their methyltransferase functions; (5) chromosome 1q contains four HMTs that are concurrently or independently amplified/overexpressed in breast cancer cell lines and primary samples; (6) we identified several HMTs, including WHSC1L1, SETDB2, and KMT2C, whose DNA copy number or mRNA expression level was significantly associated with shorter survival in breast cancer patients; and (7) integrative analysis prioritized SETDB1, WHSC1L1, and SETDB2 as the most critical HMTs in breast cancer.

The HMTs constitute a large class of enzymes that catalyze site-specific methylation of lysine residues on histones and other proteins [7-9]. Previously, oncogenic alterations, including amplification, mutation, and translocation of several HMTs, were identified in various human tumors, including breast cancer [8, 10, 11, 26, 27]. A well-studied example is EZH2, the catalytic subunit of the polycomb repressive complex 2. Hyperactivation of EZH2, by amplification/overexpression or mutation, was documented in breast and prostate cancers, lymphoma, and other types of tumors [28]. Tissue microarray analysis revealed that EZH2 protein levels were strongly associated with breast cancer aggressiveness [13, 29]. Another example is WHSC1L1, a commonly amplified gene at 8p11-12 in breast and lung cancers; WHSC1L1 is fused with NUP98 in acute myeloid leukemia [12, 30-32]. Evidence indicated that the 8p11-12 amplicon contained several candidate oncogenes in breast cancer [12]. As shown in Supplementary Figure S5, we found that most WHSC1L1-amplified breast cancer samples also showed the amplification of other candidate oncogenes at the 8p11-12 amplicon. Notably, our previous study demonstrated the oncogenic potential of WHSC1L1, particularly in ER+ Luminal breast cancer [12]. Although previous studies revealed the dysregulation of individual HMTs in breast cancer, to our knowledge, this is the first report showing comprehensive genomic and transcriptomic analysis of 51 HMTs in different types of breast cancer [10-12]. This study validates previous findings in individual HMTs, namely that WHSC1L1 is highly amplified/overexpressed in Luminal subtypes, and EZH2 is highly expressed in basal-like breast cancer [12, 23, 27]. Importantly, our results reveal the genomic landscape for many HMTs in different subtypes of breast cancer.

Previous studies demonstrated a prevalent gain/amplification of chromosome 1q in breast cancer [33-35]. Of the five HMTs that have high-level amplification in more than 10% of breast cancer samples, four are clustered on chromosome 1q, from 1q21 to 1q44. We found that, of 215 breast cancer samples in which chromosome 1q is amplified, 65 (30%) had concurrent high-level amplification in all four genetic loci; this amplification is more common in Luminal breast cancer. Furthermore, detailed genomic analysis showed that 1q amplifications were heterogeneous in most breast cancer cell lines and primary samples. The SETDB1 gene (1q21.3) encodes the H3K9 methyltransferase and showed independent amplification in 23 of 215 primary breast cancers as well as the MCF7 breast cancer cell line. We found that amplification or overexpression of SETDB1 is more common in basal-like breast cancer (Figure 1A, Figure 2, and Supplementary Table S9). Recent studies demonstrated that SETDB1 is frequently amplified in lung and urothelial cancers as well as melanoma [36-38]. The inhibition of SETDB1 expression in SETDB1-gene-amplified lung cancer cells reduced tumor growth in cell culture and nude mice models, whereas its overexpression increased tumor invasiveness [36]. SETDB1 significantly accelerated melanoma formation in a zebrafish model [38]. SMYD2 and SMYD3, which share a high degree of sequence homology, are localized at 1q32 and 1q44, respectively. We queried published TCGA breast cancer data and found that the size of the 1q44 (SMYD3) amplicon spans approximately 1.5 Mb in breast cancer [6]. Recent studies demonstrated that SMYD2 and SMYD3 can methylate both histone and nonhistone proteins, such as the tumor suppressors p53 and Rb as well as the ERα protein [39-41]. Enzymatic analysis shows that SMYD2 is a monomethyltransferase that prefers nonmethylated p53 peptide as a substrate among different histones and protein substrates tested in vitro [42]. Conversely, another study demonstrated the role of SMYD3 in ER-mediated transcription via its histone methyltransferase activity [43]. Furthermore, SMYD3 activity regulates cytoplasmic oncogenic signaling; specifically, SMYD3-mediated MAP3K2 methylation activates RAS signaling and drives carcinogenesis in vivo [44]. Additionally, ASH1L is an H3K4 and H3K36 histone methyltransferase that occupies the transcribed region of active genes [45]. Notably, H3K4 demethylase KDM5B (also known as JARID1B), which is localized at 1q32.1, was recently shown to be an oncogene in Luminal breast cancer by regulating lineage-specific genes [46]. Thus, chromosome 1q contains multiple oncogenic histone lysine modifiers that are concurrently or independently amplified or overexpressed in breast cancer. It is necessary to investigate whether or how these five histone lysine modifiers contribute, independently or cooperatively, to breast tumorigenesis.

Two HMT genes demonstrated high (>2%) rates of homozygous deletion among breast cancer samples, implying their potential roles as tumor suppressors. Of the two, PRDM7 is the more mysterious gene. Most studies of PRDM7 to date investigated its phylogenetic and evolutionary ancestry [47, 48]. The other gene, SETDB2, which was concurrently deleted with another tumor suppressor, RB1, at 13q14 (Supplementary Figure S5A), is a homologue of SETDB1 and participates in the distribution of trimethylated H3K9 (H3K9me3) marks and contributes to chromosome segregation during mitosis [49]. However, although SETDB1 and SETDB2 are homologues, they seem to have opposing functions with regard to breast cancer. Structurally, the most significant difference between the two proteins is the presence or absence of a Tandem-Tudor domain. The Tandem-Tudor domain functions essentially as the guiding module that allows a protein to recognize and bind to the appropriate histone, where it can regulate methylation reactions. For example, the Tandem-Tudor domain of 53BP1 has a direct role in recognizing and binding H4K20 dimethylation (H4K20me2) to promote DNA repair [50]. In addition, the Tandem-Tudor domain of histone H3K9 and H3K36 demethylase KDM4A recognizes and binds H3K4me3 and H4K20me3/me2 marks [51, 52]. However, the histone site and marks that the SETDB1 Tandem-Tudor domain recognizes are still not known. We still need to investigate how the presence of the Tandem-Tudor domain in SETDB1 differentiates it from SETDB2 so dramatically.

We identified the two most mutated HMT genes in breast cancer. KMT2C was mutated in 67 of 958 breast cancer specimens (6.99%), which is almost three times more than KMT2D with a rate of 2.40%. KMT2C and KMT2D belong to a set of genes known as mixed-lineage leukemia (MLL) genes and have the aliases MLL3 and MLL4, respectively. Translocation mutations cause the generated MLL proteins to lose their SET domain and fuse with other proteins to create fusion proteins, which have been identified as direct causes of aggressive leukemia [53]. In terms of function, KMT2C and KMT2D are monomethylases for the lysine residue H3K4 and are required to generate H3K4me1 at various enhancer regions throughout the genome [54]. It has been proposed that cancer-associated mutations in KMT2C and KMT2D exert their properties through the malfunction of KMT2C/KMT2D-dependent enhancers [55]. In addition, KMT2C/D can associate with activating signal cointegrator-2 (ASC-2), a multifunctional coactivator, to form an ASC complex, which has been identified as a key factor in the DNA damage response and in p53 activation [56]. Our data, which demonstrate that KMT2C is commonly mutated and that its deletion is significantly associated with shorter patient survival, suggests that KMT2C might function as a tumor suppressor in breast cancer.

Because epigenetic changes are reversible and HMTs are druggable, targeting HMTs provides a unique opportunity for pharmacologic intervention by means of designing inhibitors that represent a novel class of anti-cancer drugs. Recent evidence shows that aberrant activity of HMTs, due to amplification, deletion, or mutation of their corresponding genes, contributes to cancer initiation and progression. Consequently, a promising strategy could be to target patient populations with those alterations. Selective inhibitors of several HMTs have been reported to show antitumor effects in vitro and in vivo [57]. Furthermore, an EZH2 inhibitor (EPZ-6438) has entered phase I human clinical trials. Here, we reported a systematic and integrative analysis of HMTs and identified eight HMTs (SETDB1, SMYD3, ASH1L, SMYD2, WHSC1L1, SUV420H1, SETDB2, and KMT2C) that have the highest frequencies of genetic alterations and most clinical relevance. Our findings for these HMTs represent a strong foundation for further mechanistic research and therapeutic advances in breast cancer.

MATERIALS AND METHODS

Cell culture

The cultures for the SUM series of breast cancer cell lines and nontransformed human mammary epithelial cell MCF10A line have been described in detail previously [21, 58]. The Colo824 cell line was obtained from DMSZ, and the cell lines HCC70, HCC1187, HCC1428, HCC1937, HCC1954, MDB-MA-468, T47D, and ZR-75-1 were obtained from ATCC. These lines were maintained in RPMI with 10% FBS (Atlanta Biologicals, Flowery Branch, GA, USA) according to DMSZ and ATCC protocols.

Genomic array CGH

Genomic array CGH experiments were done using the Agilent human genome CGH microarray chip (Agilent Technologies, Palo Alto, CA, USA) as previously described in detail [21]. Agilent's CGH Analytics software was used to calculate various measurement parameters, including log2 ratios of total integrated Cy-5 and Cy-3 intensities for each probe. Array data have been posted in the NCBI GEO database (GEO accession numbers: GSM718287, GSM718288, GSM718290).

Semiquantitative RT-PCR reactions

mRNA was prepared from human breast cancer cell lines and the MCF10A cell line by using an RNeasy Plus Mini Kit (QIAGEN). mRNA was mixed with qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD, USA), then converted into cDNA through a reverse-transcription reaction for real-time PCR reactions. Primer sets for HMT genes were ordered from Life Technologies (Carlsbad, CA, USA). A PUM1 primer set was used as a control. Semiquantitative RT-PCR was done using the FastStart Universal SYBR Green Master (Rox) (Roche Diagnostics Indianapolis, IN, USA).

Genomic and clinical data

The DNA copy number, mutation, and overall survival datasets of 958 breast cancer samples used in this research were obtained from the cBio Cancer Genomics Portal at http://www.cbioportal.org. The copy number for each HMT was generated from the copy number analysis algorithms GISTIC and indicates the copy number level per gene. “-2” is a deep loss (possibly a homozygous deletion), “-1” is a heterozygous deletion, “0” is diploid, “1” indicates a low-level gain, and “2” is a high-level amplification. For mRNA expression data, the relative expression of an individual gene and the gene's expression distribution in a reference population were analyzed. The reference population was either all tumors that are diploid for the gene in question, or, when available, normal adjacent tissue. The returned value indicates the number of standard deviations away from the mean of expression in the reference population (Z-score). The breast cancer subtype information was from a previous publication [6].

Statistical analysis

Statistical analyses were performed using the R software (http://www.r-project.org) and Graphpad Prism (version 6.03). The correlations between copy numbers and mRNA levels of each HMT from 958 sequenced breast cancer specimens were analyzed using Spearman, Kendall, and Pearson correlation tests. The Spearman and Kendall tests are rank correlations—the Spearman coefficient relates the two variables conserving the order of data points, and the Kendall coefficient measures the number of ranks that match in the data set. Although the Pearson correlation coefficient is the most widely used, it was deemed the least relevant to our study, as it measures only the strength of linear relationships and ignores all others. We used the “cor” function in R statistical software for computation, specifying in the code which type of test we wanted (Spearman, Kendall, or Pearson). A systematic approach was used to analyze the correlations between the mRNA levels and DNA copy numbers for each of the 48 HMTs for all three of the methods. The difference in mRNA expression level for each HMT between the basal-like and the other cancer subtypes was calculated using Student's t-test. The association between the clinical outcome and individual HMT copy number and expression level was evaluated using a log-rank test. Multivariate survival analysis was conducted using the Cox regression function in R statistical software.

SUPPLEMENTARY MATERIALS AND METHODS FIGURES AND TABLES

Acknowledgments

This work was partially supported by grants from the Department of Defense Breast Cancer Research Program award (BC083945), the Mary Kay Foundation Cancer Research Grant Program, and the SRIG grant and Molecular Therapeutics Program Grant from the Karmanos Cancer Institute to Dr. Z-Q.Y; and by funding from the Cancer Biology Graduate Program, Wayne State University School of Medicine, to Sarah Kimball and Andreana Holowatyj. We thank Dr. Stephen P. Ethier for providing the SUM breast cancer cell lines and for his continuous encouragement.

REFERENCES

  • 1.van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–536. doi: 10.1038/415530a. [DOI] [PubMed] [Google Scholar]
  • 2.Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi: 10.1073/pnas.191367098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812–1823. doi: 10.1016/S0140-6736(11)61539-0. [DOI] [PubMed] [Google Scholar]
  • 4.Creighton CJ. The molecular profile of luminal B breast cancer. Biologics: Targets & Therapy. 2012;6:289–297. doi: 10.2147/BTT.S29923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502. doi: 10.1001/jama.295.21.2492. [DOI] [PubMed] [Google Scholar]
  • 6.Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi: 10.1038/nature11412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13(5):343–357. doi: 10.1038/nrg3173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Albert M, Helin K. Histone methyltransferases in cancer. Semin Cell Developmental Biol. 2010;21(2):209–220. doi: 10.1016/j.semcdb.2009.10.007. [DOI] [PubMed] [Google Scholar]
  • 9.Herz HM, Garruss A, Shilatifard A. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem Sci. 2013;38(12):621–639. doi: 10.1016/j.tibs.2013.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014;5(4):265–296. doi: 10.1007/s13238-014-0031-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shen H, Laird PW. Interplay between the Cancer Genome and Epigenome. Cell. 2013;153(1):38–55. doi: 10.1016/j.cell.2013.03.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 2010;70(21):8487–8497. doi: 10.1158/0008-5472.CAN-10-1013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606–11611. doi: 10.1073/pnas.1933744100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res: CR. 2013;32:70. doi: 10.1186/1756-9966-32-70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets. 2013;13(5):558–579. doi: 10.2174/1568009611313050007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Albertson DG. Gene amplification in cancer. Trends Genet. 2006;22(8):447–455. doi: 10.1016/j.tig.2006.06.007. [DOI] [PubMed] [Google Scholar]
  • 17.Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003;34(4):369–376. doi: 10.1038/ng1215. [DOI] [PubMed] [Google Scholar]
  • 18.Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun YC, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signaling. 2013;6(269) doi: 10.1126/scisignal.2004088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery. 2012;2(5):401–404. doi: 10.1158/2159-8290.CD-12-0095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Liu L, Zhen XT, Denton E, Marsden BD, Schapira M. ChromoHub: a data hub for navigators of chromatin-mediated signalling. Bioinformatics. 2012;28(16):2205–2206. doi: 10.1093/bioinformatics/bts340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res. 2006;66(24):11632–11643. doi: 10.1158/0008-5472.CAN-06-2946. [DOI] [PubMed] [Google Scholar]
  • 22.Weigelt B, Mackay A, A’Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. The Lancet Oncology. 2010;11(4):339–349. doi: 10.1016/S1470-2045(10)70008-5. [DOI] [PubMed] [Google Scholar]
  • 23.Granit RZ, Gabai Y, Hadar T, Karamansha Y, Liberman L, Waldhorn I, Gat-Viks I, Regev A, Maly B, Darash-Yahana M, Peretz T, Ben-Porath I. EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene. 2013;32(33):3886–3895. doi: 10.1038/onc.2012.390. [DOI] [PubMed] [Google Scholar]
  • 24.Lee J, Kim DH, Lee S, Yang QH, Lee DK, Lee SK, Roeder RG, Lee JW. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A. 2009;106(21):8513–8518. doi: 10.1073/pnas.0902873106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo JQ, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA, Watson MA, Saporita A, Weber JD, et al. PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2009;69(9):3955–3962. doi: 10.1158/0008-5472.CAN-08-4450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Copeland RA. Molecular pathways: protein methyltransferases in cancer. Clin Cancer Res. 2013;19(23):6344–6350. doi: 10.1158/1078-0432.CCR-13-0223. [DOI] [PubMed] [Google Scholar]
  • 27.Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet. 2013;14(11):765–780. doi: 10.1038/nrg3554. [DOI] [PubMed] [Google Scholar]
  • 28.Deb G, Thakur VS, Gupta S. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics. 2013;8(5):464–476. doi: 10.4161/epi.24532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stal O, Malmstrom P, Ferno M, Ryden L, Hegardt C, Borg A, Ringner M. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Molecular Oncol. 2012;6(5):494–506. doi: 10.1016/j.molonc.2012.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Morishita M, di Luccio E. Cancers and the NSD family of histone lysine methyltransferases. Biochim Biophys Acta. 2011;1816(2):158–163. doi: 10.1016/j.bbcan.2011.05.004. [DOI] [PubMed] [Google Scholar]
  • 31.Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A. 2005;102(27):9625–9630. doi: 10.1073/pnas.0504126102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rosati R, La Starza R, Veronese A, Aventin A, Schwienbacher C, Vallespi T, Negrini M, Martelli MF, Mecucci C. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11. 2;p15) Blood. 2002;99(10):3857–3860. doi: 10.1182/blood.v99.10.3857. [DOI] [PubMed] [Google Scholar]
  • 33.Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15(2):441–451. doi: 10.1158/1078-0432.CCR-08-1791. [DOI] [PubMed] [Google Scholar]
  • 34.Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rouge C, Ursule L, Nguyen C, Bibeau F, Rodriguez C, Theillet C. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q. Br J Cancer. 2006;95(10):1439–1447. doi: 10.1038/sj.bjc.6603433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007;67(24):11565–11575. doi: 10.1158/0008-5472.CAN-07-2536. [DOI] [PubMed] [Google Scholar]
  • 36.Rodriguez-Paredes M, Martinez de Paz A, Simo-Riudalbas L, Sayols S, Moutinho C, Moran S, Villanueva A, Vazquez-Cedeira M, Lazo PA, Carneiro F, Moura CS, Vieira J, Teixeira MR, Esteller M. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene. 2014;33(21):2807–2813. doi: 10.1038/onc.2013.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, Gudjonsson S, Liedberg F, Patschan O, Mansson W, Ferno M, Hoglund M. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012;7(6):e38863. doi: 10.1371/journal.pone.0038863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferre F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011;471(7339):513–517. doi: 10.1038/nature09806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006;444(7119):629–632. doi: 10.1038/nature05287. [DOI] [PubMed] [Google Scholar]
  • 40.Saddic LA, West LE, Aslanian A, Yates JR, 3rd, Rubin SM, Gozani O, Sage J. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem. 2010;285(48):37733–37740. doi: 10.1074/jbc.M110.137612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Zhang X, Tanaka K, Yan J, Li J, Peng D, Jiang Y, Yang Z, Barton MC, Wen H, Shi X. Regulation of estrogen receptor alpha by histone methyltransferase SMYD2-mediated protein methylation. Proc Natl Acad Sci U S A. 2013;110(43):17284–17289. doi: 10.1073/pnas.1307959110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wu J, Cheung T, Grande C, Ferguson AD, Zhu X, Theriault K, Code E, Birr C, Keen N, Chen H. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase. Biochemistry. 2011;50(29):6488–6497. doi: 10.1021/bi200725p. [DOI] [PubMed] [Google Scholar]
  • 43.Kim H, Heo K, Kim JH, Kim K, Choi J, An W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem. 2009;284(30):19867–19877. doi: 10.1074/jbc.M109.021485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014;510(7504):283–287. doi: 10.1038/nature13320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Gregory GD, Vakoc CR, Rozovskaia T, Zheng X, Patel S, Nakamura T, Canaani E, Blobel GA. Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Mol Cell Biol. 2007;27(24):8466–8479. doi: 10.1128/MCB.00993-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, Sun H, Kim JH, Carver K, Zucca M, Feng J, Almendro V, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25(6):762–777. doi: 10.1016/j.ccr.2014.04.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Sun XJ, Xu PF, Zhou T, Hu M, Fu CT, Zhang Y, Jin Y, Chen Y, Chen SJ, Huang QH, Liu TX, Chen Z. Genome-wide survey and developmental expression mapping of zebrafish SET domain-containing genes. PLoS One. 2008;3(1):e1499. doi: 10.1371/journal.pone.0001499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Fumasoni I, Meani N, Rambaldi D, Scafetta G, Alcalay M, Ciccarelli FD. Family expansion and gene rearrangements contributed to the functional specialization of PRDM genes in vertebrates. BMC Evolutionary Biol. 2007;7:187. doi: 10.1186/1471-2148-7-187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Falandry C, Fourel G, Galy V, Ristriani T, Horard B, Bensimon E, Salles G, Gilson E, Magdinier F. CLLD8/KMT1F Is a Lysine Methyltransferase That Is Important for Chromosome Segregation. J Biol Chem. 2010;285(26):20234–20241. doi: 10.1074/jbc.M109.052399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Botuyan MV, Lee J, Ward IM, Kim JE, Thompson JR, Chen J, Mer G. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell. 2006;127(7):1361–1373. doi: 10.1016/j.cell.2006.10.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Huang Y, Fang J, Bedford MT, Zhang Y, Xu RM. Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science. 2006;312(5774):748–751. doi: 10.1126/science.1125162. [DOI] [PubMed] [Google Scholar]
  • 52.Lee J, Thompson JR, Botuyan MV, Mer G. Distinct binding modes specify the recognition of methylated histones H3K4 and H4K20 by JMJD2A-tudor. Nat Struct Mol Biol. 2008;15(1):109–111. doi: 10.1038/nsmb1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Ballabio E, Milne TA. Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis. Cancers (Basel) 2012;4(3):904–944. doi: 10.3390/cancers4030904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Hu DQ, Gao X, Morgan MA, Herz HM, Smith ER, Shilatifard A. The MLL3/MLL4 Branches of the COMPASS Family Function as Major Histone H3K4 Monomethylases at Enhancers. Mol Cell Biol. 2013;33(23):4745–4754. doi: 10.1128/MCB.01181-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Herz HM, Hu DQ, Shilatifard A. Enhancer Malfunction in Cancer. Mol Cell. 2014;53(6):859–866. doi: 10.1016/j.molcel.2014.02.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Lee J, Kim DH, Lee S, Yang QH, Lee DK, Lee SK, Roeder RG, Lee JW. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A. 2009;106(21):8513–8518. doi: 10.1073/pnas.0902873106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Copeland RA, Moyer MP, Richon VM. Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics. Oncogene. 2013;32(8):939–946. doi: 10.1038/onc.2012.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ethier SP. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer. 1999;81(8):1328–1334. doi: 10.1038/sj.bjc.6695007. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oncotarget-06-2466-s001.pdf (681.9KB, pdf)
oncotarget-06-2466-s002.pdf (11.5KB, pdf)
oncotarget-06-2466-s003.pdf (7KB, pdf)
oncotarget-06-2466-s004.pdf (54.3KB, pdf)
oncotarget-06-2466-s005.pdf (372.6KB, pdf)
oncotarget-06-2466-s006.pdf (55.8KB, pdf)
oncotarget-06-2466-s007.pdf (52.5KB, pdf)
oncotarget-06-2466-s008.pdf (77.8KB, pdf)
oncotarget-06-2466-s009.pdf (64.9KB, pdf)
oncotarget-06-2466-s010.pdf (50.4KB, pdf)

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES